Search results
Results from the WOW.Com Content Network
Repaglinide caused an increased incidence in male rats of benign adenomas (tumors) of the thyroid and liver. [2] No such effect was seen with another drug of this ...
Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is a medication used in addition to diet and exercise for blood sugar control in type 2 diabetes. [ 1 ]
Glimepiride is an antidiabetic medication within the sulfonylurea class, primarily prescribed for the management of type 2 diabetes. [ 1 ] [ 2 ] It is regarded as a second-line option compared to metformin , due to metformin's well-established safety and efficacy. [ 1 ]
A study funded by Novo Nordisk, the U.S. distributor for Repaglinide, compared their product with Nateglinide in "A randomized, parallel-group, open-label, multicenter 16-week clinical trial". [1] They concluded that the two were similar, but "repaglinide monotherapy was significantly more effective than nateglinide monotherapy in reducing ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
ATC code A10 Drugs used in diabetes is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
Mitiglinide (INN, [1] trade name Glufast) is a drug for the treatment of type 2 diabetes. [2]Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda.
Imeglimin (EMD- 387008,PXL- 008,RVT-1501, brand name Twymeeg) is an oral anti-diabetic medication. [1] [2] It was approved for use in Japan in June 2021.[3]It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase muscle glucose uptake, and restore normal insulin secretion.